Legal status in the United States

Is ARA-290 legal?

Read at FDA, DEA and WADAPublished by PepVault

ARA-290 (cibinetide) has no FDA-approved product, is not a federally controlled substance, and is banned in sport (WADA’s class S2.1.5 covers it), as of November 18, 2026.

ARA-290 at a glance

CheckStatus, read Nov 18, 2026
FDA approvalNot approved
CompoundingNominated without adequate support (503A category 3)
DEA scheduleNot controlled
Sport (WADA)Banned by its class (S2.1.5)

FDA approval

ARA-290 (cibinetide) has no FDA-approved product: Drugs@FDA lists no application for it.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Compounding

FDA lists cibinetide (ARA-290) in 503A category 3, bulk substances nominated without adequate support, on its list updated May 14, 2026; it is not on FDA’s category 2 page or the 503B bulks list.

The source: “Cibinetide (ARA-290)”

DEA schedule

It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

Sport (WADA)

WADA bans it at all times, in and out of competition, by its class: S2.1.5 of the 2026 list bans “innate repair receptor agonists”, and its developer’s trial record on ClinicalTrials.gov describes ARA-290 as a peptide that “activates the innate repair receptor”.

The source: “Innate repair receptor agonists, e.g. asialo EPO; carbamylated EPO (CEPO)”

How it is sold when it isn’t approved

FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

The source: falsely labeled “for research purposes” or “not for human consumption.”

What this means and doesn’t

This page reports what the agencies’ own pages said about ARA-290 in the United States when we read them on November 18, 2026. These are records of regulators, not study evidence; for what the research shows, see the compound page.

It is not legal advice, and it doesn’t cover state laws or other countries, whose rules differ. Agencies change their lists, so each fact carries its date and a link to the page it came from.

Questions

  • Is ARA-290 FDA approved?

    ARA-290 (cibinetide) has no FDA-approved product: Drugs@FDA lists no application for it.

  • Is ARA-290 a controlled substance?

    It is not a federally controlled substance: its name is not in the DEA’s schedules (21 CFR Part 1308) or on the DEA’s alphabetical list of controlled substances.

  • Is ARA-290 banned in sport?

    WADA bans it at all times, in and out of competition, by its class: S2.1.5 of the 2026 list bans “innate repair receptor agonists”, and its developer’s trial record on ClinicalTrials.gov describes ARA-290 as a peptide that “activates the innate repair receptor”.

  • What does FDA say about compounding ARA-290?

    FDA lists cibinetide (ARA-290) in 503A category 3, bulk substances nominated without adequate support, on its list updated May 14, 2026; it is not on FDA’s category 2 page or the 503B bulks list.

  • What does FDA say about the “research use only” label?

    FDA has warned companies that sold unapproved GLP-1 drugs labeled “for research purposes” or “not for human consumption” to consumers with dosing instructions, and calls that label false. FDA’s page names GLP-1 drugs; a research label is not an FDA approval of any kind.

Read next

Track it in the app

PepVault for iPhone

Keep your own record in PepVault

Log your doses and vials, with a reminder for the next one.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo